Maze (MAZE) CSBO Atul Dandekar Exercises Options and Sells Shares

What Happened
Atul Dandekar, Chief Scientific and Business Officer (CSBO) of Maze Therapeutics, exercised stock options and sold shares on September 29, 2026. The filing shows he: exercised 7,500 option shares at $10.42 per share (acquired for $78,150), sold 7,500 shares in the open market at a weighted average price of $27.06 for proceeds of about $202,921, and also reported 7,500 shares disposed at $0.00 in connection with the derivative exercise (see footnotes).

Key Details

• Transaction date: September 29, 2026; Form 4 filed October 1, 2026 (appears timely).
• Exercise (M): 7,500 shares acquired at $10.42 each — total cost $78,150.
• Sale (S): 7,500 shares sold at a weighted average price of $27.06 — proceeds ≈ $202,921; sale prices ranged $26.47–$27.45 (footnote F2).
• Derivative disposal (M): 7,500 shares reported disposed at $0.00 (see footnote F3 re award terms).
• Footnotes: F1 — sale effected under a Rule 10b5-1 trading plan adopted Sept 29, 2025; F2 — weighted-average sale price with range provided; F3 — option was fully vested (vested March 17, 2025).
• Shares owned after the transactions: not disclosed in the provided filing.

Context
This appears to be a same-day exercise and partial sale (often called a cashless exercise/sale) where the insider exercised options and sold some of the resulting shares. The sale was executed under a pre-established 10b5-1 plan, which is a common mechanism for scheduled insider trades. The filing is factual and does not state motivation; purchases (exercising options) and sales under a plan are typically routine and should not be read as a definitive signal of future company performance.